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Background: To compare different ultrasound-based international ovarian tumour analysis (IOTA) strategies and risk of
malignancy index (RMI) for ovarian cancer diagnosis using a meta-analysis approach of centre-specific data from IOTA3.
Methods: This prospective multicentre diagnostic accuracy study included 2403 patients with 1423 benign and 980 malignant
adnexal masses from 2009 until 2012. All patients underwent standardised transvaginal ultrasonography. Test performance of RMI,
subjective assessment (SA) of ultrasound findings, two IOTA risk models (LR1 and LR2), and strategies involving combinations of
IOTA simple rules (SRs), simple descriptors (SDs) and LR2 with and without SA was estimated using a meta-analysis approach.
Reference standard was histology after surgery.
Results: The areas under the receiver operator characteristic curves of LR1, LR2, SA and RMI were 0.930 (0.917–0.942), 0.918
(0.905–0.930), 0.914 (0.886–0.936) and 0.875 (0.853–0.894). Diagnostic one-step and two-step strategies using LR1, LR2, SR and SD
achieved summary estimates for sensitivity 90–96%, specificity 74–79% and diagnostic odds ratio (DOR) 32.8–50.5. Adding SA
when IOTA methods yielded equivocal results improved performance (DOR 57.6–75.7). Risk of Malignancy Index had sensitivity
67%, specificity 91% and DOR 17.5.
Conclusions: This study shows all IOTA strategies had excellent diagnostic performance in comparison with RMI. The IOTA
strategy chosen may be determined by clinical preference.
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Providing care within highly specialised multidisciplinary services
has a clear survival benefit for patients with ovarian cancer (Woo
et al, 2012). Although such centralised care is recommended in
many developed countries, a large proportion of ovarian cancer
patients remain treated by general surgeons and physicians
(Verleye et al, 2010). Several factors probably contribute to this
failure to refer for specialist care, but the lack of effective
preoperative strategies to evaluate ovarian tumours is certainly
one of the most important factors (Miller and Ueland, 2012).
Reports from the international ovarian tumour analysis (IOTA)
multicentre studies phase 1, 1b, 2 and 4 (Timmerman et al, 2005,
2007, 2008, 2010a, b; Van Holsbeke et al, 2009, 2012; Ameye et al,
2012; Kaijser et al, 2013; Sayasneh et al, 2013a, b) have
demonstrated that IOTA ultrasound-based approaches to char-
acterise adnexal masses in the hands of physicians and sonogra-
phers with varying levels of experience outperform other
established strategies such as use of individual biomarkers (serum
CA-125), the Risk of Malignancy Index (RMI; Jacobs et al, 1990) or
Risk of Ovarian Malignancy Algorithm (Moore et al, 2009), for the
classification of ovarian pathology. Nevertheless, there is a paucity
of comprehensive prospective studies comparing different diag-
nostic strategies for ovarian cancer diagnosis on the same study
population. Such studies are of pivotal importance for assessing
diagnostic test accuracy. In the most recently published meta-
analysis, only a small number of the studies included validated
different diagnostic tests for ovarian cancer on the same data set
(Kaijser et al, 2014).
The primary aim of this study, the IOTA phase 3 study, was to
compare the test performance of various IOTA diagnostic
strategies and RMI on prospectively collected data from a large
number of patients and centres.
MATERIALS AND METHODS
Study design. This was a multicentre cross-sectional diagnostic
accuracy study with prospective data collection. Patients were
recruited between October 2009 and May 2012, in 18 centres in six
countries (Sweden, Belgium, Italy, Poland, Spain and Czech
Republic). These centres were either oncology referral centres
(i.e., tertiary centres for the treatment of women with gynaecolo-
gical malignancy) or general hospitals and units with a special
interest in gynaecological ultrasound. The centres and type of
centres in IOTA3 are listed in a Supplementary Appendix. All
centres except three (SSW, BSP and FIT) had participated in at
least one of the previous IOTA studies (1, 1b or 2). Ethics approval
was obtained by the ethics committee of the University Hospitals
Leuven as main investigating centre (B32220095331/S51375) as
well of the local committees of all contributing centres to IOTA3.
Inclusion criteria. Patients were eligible if they presented with at
least one adnexal mass (ovarian, para-ovarian or tubal), underwent
transvaginal ultrasound examination by a principal investigator at
one of the participating centres and were then selected for surgical
intervention by the managing clinician. Patients were examined
following the research protocol if they gave informed consent. If
more than one adnexal mass was detected, the mass with the most
complex ultrasound morphology was denoted by the ultrasound
examiner as the dominant mass, that is, the one to be used for
statistical analysis. If both masses had similar morphology, the
largest one or the one most easily accessible by ultrasound was
denoted dominant.
Exclusion criteria. Exclusion criteria were surgical removal of the
mass 4120 days after the ultrasound examination, pregnancy at
scan and data inconsistencies that persisted after final manual data
checks.
Data collection. A dedicated, secure electronic data-collection
system was developed for the study (IOTA3 Study Screen; Astraia
Software, Munich, Germany). Patients automatically received a
unique identifier. Data security was ensured by encrypting all data
communication. Data integrity and completeness were ensured by
client-side checks in the system supplied by Astraia and final data
cleaning by a group of biostatisticians and expert ultrasound
examiners in Leuven, Belgium.
Ultrasound examination. All included patients underwent stan-
dardised transvaginal ultrasonography by examiners experienced
in gynaecologic ultrasound (level III) (Education, Practical
Standards Committee, European Federation of Societies for
Ultrasound in Medicine and Biology, 2006). High-end ultrasound
systems, the same or similar to those in IOTA phase 1 and 2, were
used. Grey scale and colour Doppler ultrasound imaging was used
to obtain information on 440 morphological and blood-flow
variables to characterise each adnexal mass. Details on the
ultrasound examination technique and the IOTA terms and
definitions used to describe adnexal pathology have been published
elsewhere (Timmerman et al, 2000). After completing the
ultrasound examination, the ultrasound examiner classified each
mass as benign or malignant on the basis of his/her subjective
assessment (SA) of grey scale and colour or power Doppler
ultrasound findings. Each mass was classified as certainly benign,
probably benign, uncertain but most probably benign, uncertain
but most probably malignant, probably malignant or certainly
malignant. The ultrasound information was recorded prospectively
in the electronic data-collection system, was locked at the time of
the examination and could not be changed thereafter. Predictions
of all diagnostic strategies under consideration (except SA) were
obtained centrally after the conclusion of the study, and had no
role in the decision-making process. Decision-making regarding
surgery for adnexal tumours was based on clinical information
(such as symptoms, age, operative risk, coexisting disease, etc.) and
on the clinical ultrasound report. The clinical ultrasound report
was written on the basis of the results of SA.
Serum tumour marker. Centres were encouraged to measure the
level of serum CA-125 from all patients, but the availability of this
biochemical end point was not a requirement for recruitment into
the study.
Diagnostic strategies. The methods and strategies prospectively
compared on the IOTA3 data set are SA, two IOTA logistic
regression models, that is, LR1 and LR2 (Timmerman et al, 2005),
the IOTA Simple Rules (SRs; Timmerman et al, 2008), the IOTA
Simple Descriptors (SDs; Ameye et al, 2012) and various
combinations of these, and the RMI. The IOTA methods are
briefly described in Table 1. Details can be found in the literature
(Timmerman et al, 2005, 2008; Ameye et al, 2012).
We evaluated five one-stage strategies, five two-stage strategies
and two three-stage strategies.
The one-stage strategies are: the use in all patients of either LR1,
LR2, SA, RMI or SRs (classifying all tumours where the SRs yield
an inconclusive result as malignant).
The two-step strategies are: SRs as a first stage test and SA for
tumours in which SRs yield an inconclusive result; LR2 as a first
stage test and SA for tumours in which LR2 yields a predicted risk
of malignancy ofX5% buto25% (risk of malignancy ofX5% but
o25% arbitrarily being taken to represent an equivocal result); SDs
as a first stage test, SRs for tumours unclassifiable by the SDs and
tumours unclassifiable by the SRs classified as malignant; SDs as a
first stage test and LR2 for those tumours where the SDs are
not applicable; SDs as a first stage test and SA for those tumours in
which the SDs are not applicable.
The three-step strategies are: SDs as a first stage test, SRs for
tumours in which the SDs are not applicable and SA for masses in
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which SRs are inconclusive; SDs as a first stage test, LR2 for
tumours in which the SDs are not applicable and SA for masses in
which LR2 yields a predicted risk of X5% but o25%.
Reference standard. The reference standard was the histologic
classification of the excised mass as malignant or benign.
Histological examination was carried out at the local centre.
Central pathology review was not performed because in previous
IOTA studies no significant differences in reported outcomes were
observed between local and central pathology reports (Timmerman
et al, 2005). Malignant tumours were classified according to the
criteria recommended by the International Federation of Gynae-
cology and Obstetrics (Heintz et al, 2003). Borderline ovarian
tumours were classified as malignant. The pathologist was blinded
to the prediction outcomes of the index tests being compared.
Statistical analysis. We evaluated all strategies in terms of their
ability to discriminate between benign and malignant masses. For
the logistic regression models LR1 and LR2 (for details, see
Table 1) and for RMI, the area under the receiver-operating
characteristic curve (AUC) was computed. Using the six levels of
diagnostic confidence, an AUC could also be constructed for SA.
For all strategies, we calculated sensitivity, specificity, positive and
negative likelihood ratio (LRþ and LR–) and diagnostic odds ratio
(DOR; Deeks, 2001). To do this for LR1, LR2 and RMI, we used the
cutoffs suggested in previous work (i.e., risk of malignancy X10%
indicating malignancy when using LR1 and LR2, and RMI 4200
indicating malignancy). To recognise that performance may differ
across centres, results were computed using meta-analysis
techniques (Riley et al, 2008; Macaskill et al, 2010; Van Klaveren
et al, 2014). To obtain the average AUC and DOR estimates,
random effects meta-analysis was performed, using the logit of the
AUC or the log of the DOR as the outcome variable. Sensitivity
and specificity were modelled simultaneously using random centre
effects. LRþ and LR– were computed based on the estimated
average sensitivity and specificity levels. Forest plots for LR2, SRs
and RMI were used to present centre-specific and combined
results. Subgroup analyses for RMI and the most extensively
validated IOTA methods (i.e., LR2 and SRs) (Timmerman et al,
2010a; Hartman et al, 2012; Nunes et al, 2012, 2013; Alca´zar et al,
2013; Sayasneh et al, 2013a, b) were performed for pre- and
postmenopausal women.
For LR2, we also assessed calibration, that is, we tested the extent
to which the estimated risks of malignancy corresponded to the
observed prevalence of malignancy. This was carried out by
constructing parametric (logistic) calibration curves per centre
(Cox, 1958; Steyerberg, 2009; Bouwmeester et al, 2013). Risk of
Malignancy Index and SRs do not provide risk estimates but
comparable centre-specific curves were obtained for RMI and SRs in
the following manner. For RMI, analogous logistic curves were
constructed to link RMI values (based on log (RMIþ 1)) to observed
risks. For SRs, the proportion of malignant masses was calculated for
each classification level (benign, inconclusive and malignant).
CA-125 is not a mandatory variable in the IOTA studies and by
consequence information on CA-125 was missing in 40% of the
patients. It is most likely that missing values mainly arose when
investigators did not consider CA-125 measurement necessary given
the clinical situation and the ultrasound appearance of the mass. We
used multiple imputation to handle the missing values (Sterne et al,
2009). We used all patients from phases 1, 1b, 2 and 3 for the
imputation analysis. The method is described in more detail in a
Supplementary appendix and elsewhere (Van Calster et al, 2011).
Calculations were performed using SAS 9.3 (SAS Institute, Cary,
NC, USA). Forest plots were created in R (www.r-project.org)
using the rmeta package.
When writing this article, we used the Standards for Reporting
of Diagnostic Accuracy (STARD) guidelines (Bossuyt et al, 2003).
RESULTS
In total, 2541 women with adnexal masses were enrolled in this
study. One hundred thirty-eight women were excluded from the
final data set. Reasons for exclusion were: an interval of4120 days
Table 1. Description of the IOTA methods evaluated in the IOTA study phase 3
IOTA method Variables or features
LR1 10 (risks X10%
indicate malignancy)
(1) Personal history of ovarian cancer (yes, 1; no, 0), (2) current use of hormonal therapy (yes, 1; no, 0), (3) age of the patient (in years),
(4) maximum diameter of lesion (in mm), (5) tender mass at examination (yes, 1; no, 0), (6) ascites (yes, 1; no, 0), (7) blood flow in papillary
projection (yes, 1; no, 0), (8) purely solid tumour, (9) maximum diameter of the largest solid component (in mm, but with no increase
450mm), (10) irregular internal cyst walls (yes, 1; no, 0), (11) acoustic shadows (yes, 1; no, 0), and (12) colour flow score (1–4, where
1 is no flow and 4 is maximum flow).
The mathematical formula is presented in Supplementary Appendix.
LR210, (risks X10%
indicate malignancy)
(1) Ascites (yes, 1; no, 0), (2) blood flow in papillary projection (yes, 1; no, 0), (3) maximum diameter of the largest solid component
(in mm, but with no increase 450mm), (4) irregular internal cyst walls (yes, 1; no, 0), (5) acoustic shadows (yes, 1; no, 0), (6) age of
the patient (in years).
The mathematical formula is presented in Supplementary Appendix.
IOTA SRs11,a Benign features: unilocular tumour (B1), largest diameter of largest solid component o7mm (B2), acoustic shadows (B3), smooth
multilocular tumour with largest diameter o100mm (B4), no intratumoural blood flow at colour or power Doppler (B5).
Malignant features: irregular solid tumour (M1), ascites (M2), At least four papillary projections (M3), irregular multilocular solid
tumour with largest diameter X100mm (M4), very strong intratumoural blood flow at colour or power Doppler (M5).
IOTA SDs12,b Benign descriptors: unilocular tumour with ground glass echogenicity in a premenopausal woman; unilocular tumour with mixed
echogenicity and acoustic shadows in a premenopausal woman; unilocular anechoic tumour with regular walls and maximum diameter
of lesiono10 cm; remaining unilocular tumours with regular walls.
Malignant descriptor: tumour with ascites and at least moderate colour Doppler blood flow in a postmenopausal woman; age450 years
and CA-125 4100Uml–1.
Abbreviations: IOTA¼ international ovarian tumour analysis; LR1¼ logistic regression model 1; LR2¼ logistic regression model 2; SDs¼ simple descriptors; SR¼ simple rules.
aA mass is classified as malignant if at least one M-feature and none of the B-features are present and vice versa. If no B or M features are present, or if both B and M features are present, then
the rules are considered inconclusive (unclassifiable mass), and a second stage test should be used in the unclassifiable tumours.
bA mass classified as malignant if at least one malignant descriptor and none of the benign descriptors are present and vice versa. If no benign or malignant descriptors are present, or if both
benign and malignant descriptors are present, then the descriptors are inconclusive (unclassifiable mass), and a second stage test should be used in the unclassifiable tumours.
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between ultrasonography and surgery (n¼ 66), pregnancy
(n¼ 31), data errors that could not be solved by contacting the
respective principal investigators (n¼ 28) and incomplete final
histology (n¼ 13). The final data set included 2403 patients with
1423 (59%) benign and 980 (41%) malignant adnexal masses.
There were 1049 postmenopausal patients (44%) and 1354 (56%)
premenopausal patients. The prevalence of malignancy was 28%
(378 out of 1354) in premenopausal patients and 57% (602 out of
1049) in postmenopausal patients.
The types of benign and malignant tumours based on histology
and FIGO staging in the final data set are presented in Table 2. The
most common benign diagnoses were endometrioma, serous
cystadenoma and teratoma. There were 633 out of 2403 (26.3%)
primary invasive ovarian cancers, 153 out of 2403 (6.4%)
borderline ovarian tumours, 126 out of 2403 (5.2%) metastatic
cancers in the ovaries and 68 out of 2403 (2.8%) rare primary
invasive ovarian malignancies (e.g., granulosa cell tumour, Sertoli–
Leydig cell tumour or dysgerminoma). Descriptive statistics for the
variables included in LR1, LR2 and the SRs in benign and
malignant adnexal masses are shown in Table 3.
The test performance of the IOTA diagnostic strategies, SA and
RMI when using a meta-analysis approach on centre-specific data
are presented in Table 4. The logistic regression models LR1 (AUC
0.930; 0.917–0.942) and LR2 (AUC 0.918; 0.905–0.930) had
diagnostic performance similar to expert SA (AUC 0.914;
0.886–0.936). The AUC of RMI was 0.875 (0.853–0.894). The
IOTA risk models LR1 and LR2, and strategies using various
combinations of SRs, SDs and LR2 achieved sensitivity 90–96%
and specificity 74–79% (Table 4). When expert SA was used in case
SRs or SDs or both yielded an inconclusive result, or in the event
that LR2 gave a risk X5% but o25%, specificity increased from
74–79% to 85–89% with slightly reduced sensitivity in most
instances (Table 4). The sensitivity of RMI was 67% and the
specificity 91%. LR2 yielded a risk ofX5% buto25% in 419 of the
2403 patients (17%), and 108 (26%) of these women had a
malignant adnexal mass.
The IOTA SRs were applicable in 1846 patients (76.8%) and
could be applied slightly more frequently in premenopausal (1055
out of 1354) (77.9%) than postmenopausal women (791 out of 1049)
(75.4%). In total, 1090 tumours were classified as benign by the
SRs, and this was correct in 1044 cases (95.8%), 756 tumours were
classified as malignant by the SRs and this was correct in 674 cases
(89.2%). When the SRs were applicable they achieved a sensitivity
of 94% (674 out of 720) and a specificity of 93% (1044 out of 1126).
The malignancy rate among tumours where the SRs yielded an
inconclusive result was 46.7% (260 out of 557). A strategy that
used SRs as a first stage test and classified all inconclusive cases
as malignant yielded a sensitivity of 95% (95% CI 93–97%) and a
specificity of 74% (95% CI 68–80%; Table 4). Using SA by an
expert examiner when SRs yielded an inconclusive result lowered
the sensitivity from 95 to 92% (89–94%) but increased the
specificity from 74 to 89% (85–92%; Table 4).
The IOTA SDs could be applied in 1014 (42.2%) masses. The
SDs classified 549 tumours (23% of all tumours in the study) as
Table 2. Overview of tumour types
Pathology Frequency (n) Percent (%)
Benign masses
Endometrioma 344 14.3
Serous cystadenoma 259 10.8
Teratoma 231 9.6
Mucinous cystadenoma 183 7.6
Fibroma 130 5.4
Simple cyst or parasalpingeal cyst 106 4.4
Rare benigna 48 2.0
Hydrosalpinx or salpingitis 47 2.0
Functional cyst 40 1.7
Peritoneal pseudocyst 18 0.8
Abscess 17 0.7
Malignant masses
Primary invasive stage I 128 5.3
Primary invasive stage II 47 2.0
Primary invasive stage III 397 16.5
Primary invasive stage IV 61 2.5
Borderline stage I 135 5.6
Borderline stage II 6 0.3
Borderline stage III 12 0.5
Rare primary invasiveb 68 2.8
Metastatic 126 5.2
Total 2403 100
aFor example, Brenner tumour or struma ovarii.
bFor example, dysgerminoma, granulosa cell tumour, yolk sac tumour or malignant teratoma.
Table 3. Results with regard to the variables included in LR1, LR2 and the
Simple Rules in benign and malignant adnexal masses
Variable Statistics
Benign
(1423,
59%)
Malignant
(980, 41%)
Variables in LR1 and LR2
Age (years) Median (IQR) 44 (33–56) 57 (46–66)
Largest diameter of lesion (mm) Median (IQR) 64 (47–90) 86 (56–126)
Solid components N (%) 472 (33%) 915 (93%)
Largest diameter of solid component if
present (mm)
Median (IQR) 28 (13–54) 59 (37–87)
Colour score (1–4)
Colour score 1 N (%) 574 (40) 32 (3)
Colour score 2 N (%) 563 (40) 199 (20)
Colour score 3 N (%) 239 (17) 442 (45)
Colour score 4 N (%) 47 (3) 307 (31)
Ascites N (%) 18 (1%) 322 (33%)
Papillations with detectable blood flow N (%) 55 (4%) 160 (16%)
Irregular cyst walls N (%) 385 (27%) 572 (58%)
Acoustic shadows N (%) 265 (19%) 34 (3%)
Tender mass at ultrasound examination N (%) 233 (16%) 111 (11%)
Current use of hormonal therapy N (%) 153 (11%) 54 (6%)
Personal history of ovarian cancer N (%) 14 (1%) 30 (3%)
Solid tumour N (%) 154 (11%) 473 (48%)
Variables in the simple rules
Benign ultrasound features in the simple rules
Unilocular tumour (B1) N (%) 595 (42%) 5 (0.5%)
Largest diameter of largest solid
component o7mm (B2)
N (%) 40 (3%) 2 (0.2%)
Acoustic shadows (B3) N (%) 265 (19%) 34 (3%)
Smooth multilocular tumour with
largest diameter o100mm (B4)
N (%) 224 (16%) 13 (1%)
No intratumoural blood flow at
colour or power Doppler (B5)
N (%) 574 (40%) 32 (3%)
Malignant ultrasound features in the simple rules
Irregular solid tumour (M1) N (%) 16 (1%) 189 (19%)
Ascites (M2) N (%) 18 (1%) 322 (33%)
At least 4 papillary projections (M3) N (%) 27 (2%) 91 (9%)
Irregular multilocular solid tumour
with largest diameterX100mm (M4)
N (%) 40 (3%) 153 (16%)
Very strong intratumoural blood flow
at colour or power Doppler (M5)
N (%) 47 (3%) 307 (31%)
Abbreviations: IQR¼ interquartile range; LR1¼ logistic regression model 1; LR2¼ logistic
regression model 2.
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benign of which 2 (0.4%) turned out to be malignant. The two
misclassified malignancies were stage I borderline tumours. The
SDs classified 465 tumours (19% of all tumours in the study) as
malignant, and 430 (92.5%) proved to be so. The 35 benign
tumours misclassified as malignant by the SDs consisted of 11
serous cystadenomas, 10 fibromas, 7 mucinous cystadenomas, 4
rare benign tumours, 2 teratomas and 1 functional cyst. A total
of 1389 (58%) tumours could not be categorised with the SDs.
The SRs could be applied in 66% (912 out of 1389) of the tumours
unclassifiable by the descriptors. The combination of SDs with SRs
characterised 80% (1926 out of 2403) of all masses as benign or
malignant. When a three-step strategy was applied (SDs as first
stage test, SRs in tumours unclassifiable by the descriptors and SA
for masses in which the SRs were inconclusive), sensitivity and
specificity were 93% (95% CI 90–95%) and 88% (95% CI 84–91%),
respectively (Table 4).
Table 5 shows the test performance of LR2, SRs and RMI in pre-
and postmenopausal patients when using a meta-analysis approach
of centre-specific data. In both pre- and postmenopausal patients,
the IOTA strategies had higher sensitivity and lower specificity
than RMI. The use of SA for masses not classifiable by the SRs
appeared to resolve the differences in specificity.
The sensitivity and specificity of LR2, SRs and RMI for
histological subtypes of malignant disease and the absolute number
of false-negative results for histological subtypes of malignancy are
presented in Supplementary Tables S1–S4. The sensitivity with
regard to borderline tumours, FIGO stage I invasive cancer and
metastatic disease was much higher for the main IOTA approaches
than for RMI, and the AUCs for LR2 were larger than those for
RMI for these subtypes of malignancy.
Figure 1 and Supplementary Figure S1 illustrate the variation in
number of included masses, prevalence of malignancy and inter-
centre differences in test performance (sensitivity and specificity)
for LR2, SRs combined with subjective expert assessment, SRs and
classifying inconclusive tumours as malignant, and RMI. The
malignancy rate varied between 0 and 69%, whereas the number of
enrolled cases per centre ranged from 6 to 443. For LR2 and SRs,
differences between centres in sensitivity were smaller than
differences in specificity, whereas the inverse held true for RMI.
Both IOTA methods had a higher sensitivity for cancer than RMI,
irrespective of the prevalence of malignancy. Discrimination
(AUCs) for LR2 was consistent in both oncology and non-
oncology centres with a few exceptions for centres that enrolled a
Table 4. Test performance of the IOTA diagnostic strategies, subjective assessment and RMI when using a meta-analysis approach on centre-specific
data
Approach AUC (95% CI) Sens, % (95% CI) Spec, % (95% CI) LRþ LR– DOR (95% CI)
One-step strategies
LR1 0.930 (0.917–0.942) 93.7 (91.4–95.4) 77.6 (70.9–83.0) 4.17 0.08 40.8 (30.0–55.4)
LR2 0.918 (0.905–0.930) 90.2 (86.9–92.8) 78.9 (73.2–83.7) 4.28 0.12 31.2 (23.1–42.2)
SA 0.914 (0.886–0.936) 92.5 (89.4–94.8) 87.7 (83.2–91.2) 7.53 0.09 72.9 (49.8–107)
RMI 0.875 (0.853, 0.894) 67.1 (61.4–72.4) 90.6 (87.3–93.1) 7.15 0.36 17.5 (13.1–23.4)
SRMal NA 95.3 (93.1–96.9) 74.1 (67.7–79.7) 3.68 0.06 49.1 (34.9–69.0)
Two-step strategies
SRþ SA NA 91.8 (89.1–93.9) 89.0 (85.2–92.0) 8.38 0.09 75.7 (55.6–103)
LR2þSA NA 92.3 (89.5–94.5) 84.8 (80.4–88.3) 6.06 0.09 58.7 (43.4–79.4)
SDþSRMal NA 95.7 (93.5–97.1) 73.6 (66.7–79.5) 3.62 0.06 50.5 (35.7–71.6)
SDþ LR2 NA 91.1 (88.1–93.5) 78.1 (72.4–82.9) 4.17 0.11 32.8 (24.6–43.7)
SDþSA NA 93.0 (90.0–95.1) 86.5 (81.8–90.1) 6.88 0.08 68.5 (47.7–98.3)
Three-step strategies
SDþSRþ SA NA 92.5 (89.6–94.6) 87.6 (83.5–90.7) 7.44 0.09 70.7 (51.7–96.5)
SDþ LR2þSA NA 93.1 (90.5–95.0) 83.7 (79.2–87.4) 5.71 0.08 57.6 (42.3–78.6)
Abbreviations: AUC¼ area under the receiver-operating characteristics curve; CI¼ confidence interval; DOR¼diagnostic odds ratio; IOTA¼ international ovarian tumour analysis;
LRþ ¼positive likelihood ratio; LR–¼ negative likelihood ratio; LR1¼ logistic regression model 1; LR2¼ logistic regression model 2; LR2þ SA¼ LR2 as a first stage test and SA for tumours in which
LR2 yields a predicted risk of malignancy of X5% but o25%; NA¼not applicable; RMI¼ risk of malignancy index; RMI-1¼ risk of malignancy index-1; SA¼ subjective assessment; SD¼ simple
descriptor; SDþ SRMal¼ SDs as a first stage test, SRs for tumours unclassifiable by the descriptors with all tumours in which SRs are inconclusive being classified as malignant; SDþ LR2¼SDs as
a first stage test and LR2 for those tumours in which the descriptors are not applicable; SDþSA¼ SDs as a first stage test and SA for those tumours in which the SDs are not applicable;
SDþ SRþ SA¼SDs as a first stage test, SRs for tumours in which the descriptors are not applicable, and SA for masses in which the SRs are inconclusive; SDþ LR2þ SA¼SDs as a first stage test,
LR2 for tumours in which the descriptors are not applicable, and SA for masses in which LR2 yields a predicted risk of X5% but o25%; Sens¼ sensitivity; Spec¼ specificity; SR¼ simple rules;
SRMal¼ SRs as a first stage test with all tumours in which SRs are inconclusive being classified as malignant; SRþSA¼ SRs as a first stage test and SA for tumours in which the SRs are inconclusive.
Table 5. Test performance of LR2, Simple Rules and RMI in pre- and
postmenopausal patients using a meta-analysis approach on centre-
specific data
Diagnostic method AUC (95% CI)
Sens, %
(95% CI)
Spec, %
(95% CI)
Premenopausal patients
LR2 0.908 (0.886–0.926) 85 (78–90) 82 (77–87)
SRMal 95 (91–97) 77 (70–83)
SRþSA 92 (86–95) 91 (87–94)
RMI 0.867 (0.837–0.892) 53 (45–61) 94 (92–96)
Postmenopausal patients
LR2 0.897 (0.872–0.917) 94 (92–96) 65 (58–71)
SRMal 96 (93–97) 66 (59–73)
SRþSA 93 (90–95) 83 (78–87)
RMI 0.850 (0.805–0.887) 78 (72–83) 81 (76–85)
Abbreviations: AUC¼ area under the receiver-operating characteristics curve;
CI¼ confidence interval; IOTA¼ international ovarian tumour analysis; LR2¼ logistic
regression model 2; RMI¼Risk of Malignancy Index; RMI-1¼ risk of malignancy index-1;
Sens¼ sensitivity; Spec¼ specificity; SRMal¼ a one-step strategy using the IOTA Simple
Rules as a first stage test and classifying tumours where the simple rules yield an
inconclusive result as malignant; SRþSA¼ a two-stage strategy using the IOTA simple
rules as a first stage test and using subjective assessment for those tumours where the
simple rules yield an inconclusive result.
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very small number of cases (Supplementary Figure S2). Discrimi-
nation for RMI showed some variation between the centres
(Supplementary Figure S3). The summary estimates of test
performance of LR2, SRs and RMI were similar irrespective of
whether it was estimated using pooled data or meta-analysis.
However, pooling underestimates uncertainty, while uncertainty is
appropriately addressed by adopting meta-analysis techniques.
Figure 2 shows the results of calibration for LR2, RMI and SRs
for the nine centres that contributed the largest number of patients.
Calibration results differed between centres. This means that for a
specific prediction from a diagnostic test (LR2 risk, RMI value or
SRs category) the observed prevalence of malignancy varies
between centres. For LR2, the risk of malignancy was under-
estimated in seven of the nine centres (calibration curves above the
diagonal), slightly overestimated in one centre and perfectly
calibrated in one centre. The prevalence of malignancy in women
with a RMI score of 200 varied between centres from 30 to 70%,
and RMI values of 200 or more were associated with high
malignancy rates.
DISCUSSION
This comparison of IOTA risk prediction models and diagnostic
strategies in different clinical environments using a meta-analysis
approach showed excellent test performance for all IOTA methods
to characterise adnexal masses before surgery. All IOTA strategies
manifested better discrimination than RMI. In addition, we have
demonstrated inter-centre differences in test performance and
calibration for LR2, SRs and RMI. Our use of meta-analysis
techniques to summarise data did not meaningfully change the
summary measures of performance from those obtained with a
standard pooled analysis but gave wider confidence intervals
properly reflecting the uncertainty caused by differences between
centres.
The strengths of this report include the use of a rigorous
prospective ultrasound protocol with agreed terms, measurement
techniques and definitions; the use of advanced statistical methods
to synthesise multicentre data and report summary estimates of
test accuracy and calibration, thereby minimising the risk that
results are overly influenced by a single centre recruiting many
more patients than others; and the large number of patients, the
many participating centres and the different types of participating
centres making our results highly likely to be generalisable.
A limitation of our study is that the SRs, SDs and the two-step and
three-step strategies were not directly applied when scanning the
patients. Instead, 440 clinical and ultrasound variables were
prospectively collected from each patient and later incorporated in
the SRs or SDs, or synthesised to become descriptors in the SDs or
features in the SRs. Although this may not have influenced the
performance of SA or of LR1 or LR2, it could have affected that of
the other tests and of the two-step and three-step strategies.
A second limitation is that information on CA-125 was missing in
40% of cases. We solved this by using multiple imputation (Sterne
et al, 2009; Van Calster et al, 2011). Two sensitivity analyses using
only complete cases for CA-125 confirmed the difference in test
performance in favour of the IOTA methods (LR2 and SRs)
(Supplementary Tables S5 and S6). However, these approaches are
biased because CA-125 is more often missing in tumours that are
easy to diagnose and more likely to be benign (Supplementary
Table S7). This explains why model performance was slightly
poorer for all methods when they were tested only in cases with
available CA-125 results. For this reason, multiple imputation is
generally considered a more appropriate method to deal with
missingness than to analyse only data with complete information
(Sterne et al, 2009). A third limitation is that most of the patients
in the IOTA phase 3 study were scanned by the same experienced
examiners as in the centres where the IOTA methods were
developed, or by examiners that had already adopted the IOTA
examination technique and terminology. This may explain why the
results of IOTA phase 3 confirm those of previous IOTA studies
that showed excellent test performance of all IOTA strategies
(Timmerman et al, 2005, 2007, 2008, 2010a, b; Van Holsbeke et al,
2009, 2012; Ameye et al, 2012; Kaijser et al, 2013; Sayasneh et al,
2013a, b). On the other hand, validation studies of LR1, LR2 and
SRs performed outside IOTA studies reported similar results
(Hartman et al, 2012; Nunes et al, 2012, 2013; Alca´zar et al, 2013),
and there is now evidence that the IOTA strategies retain their
performance in the hands of sonographers and relatively
inexperienced doctors (Hartman et al, 2012; Nunes et al, 2012,
2013; Alca´zar et al, 2013; Sayasneh et al, 2013a, b).
Our results showing that the IOTA methods and strategies have
excellent ability to discriminate between benign and malignant
adnexal masses and are superior to RMI in this regard are in line
with other validation studies (Timmerman et al, 2010a; Van
Holsbeke et al, 2012; Sayasneh et al, 2013a, b) and a recent
systematic review (Kaijser et al, 2014). The conclusion of the
review was that an evidence-based approach to the preoperative
characterisation of adnexal masses should incorporate the use of
IOTA SRs or LR2 instead of RMI, particularly in women of
reproductive age (Kaijser et al, 2014).
Our multicentre study demonstrated differences in test
performance between centres for LR2, SRs and RMI. However,
in all centres, also in those with a low observed prevalence of
malignancy, the sensitivity with regard to malignancy was much
higher for the IOTA methods than for RMI. The overall
discriminative capacity (AUC) for LR2 and RMI did not seem to
be affected by cancer prevalence. However, our study highlighted
important differences in calibration results for LR2, SRs and RMI.
Type of centre appeared to contribute to these differences:
oncology centres have a higher prevalence of malignant tumours
and suffered from underestimation of the predicted risk. This was
also noticeable for SRs and RMI although these methods do not
directly provide an estimated risk. For example, for RMI we can
derive that the implicit average risk at an RMI value of 200 is 54%.
This implies that at this (commonly used) cutoff, in some centres
patients with a risk of malignancy of 450% may be classified as
low risk.
We did not undertake a full meta-regression analysis
(van Houwelingen et al, 2002) to explain in detail the inter-centre
differences in results for test performance and calibration as this is
beyond the scope of this article. The most plausible explanations
are differences in study populations (e.g., patients’ age, body mass
index or tumour mix), equipment and examiners’ use of the IOTA
terms. However, the variation between centres of the observed
(true risk) versus predicted risks for ovarian cancer revealed by this
meta-analysis highlights that caution is needed when interpreting
and using diagnostic test results (that is, risks) for individual
patient management within the context of a single centre. Future
studies should explore the reasons for differences in diagnostic
performance and calibration of diagnostic approaches between
different centres, the final aim being to improve risk prediction for
ovarian cancer.
Subjective assessment of grey scale and Doppler ultrasound
findings by a very experienced ultrasound examiner has been
suggested to be the preferred approach to characterise adnexal
masses (Valentin et al, 2001). Unfortunately, most gynaecologists,
radiologists and sonographers have limited experience with the use
of SA of ultrasound images to discriminate between benign and
malignant adnexal masses. As SRs, SDs and LR2 have been shown
to perform very well in the hands of both sonographers and
gynaecologists with limited ultrasound experience (Hartman et al,
2012; Nunes et al, 2012, 2013; Alca´zar et al, 2013; Sayasneh et al,
2013a, b), they could be used as first stage tests, and patients with
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Figure 1. The sensitivity (Sens) and specificity (Spec) for LR2 (A), Risk of Malignancy Index (B) and a two-stage strategy using SRs as a first stage test
and using SA for tumours in which the SRs are inconclusive (C) per contributing centre and for all centres combined using a meta-analysis approach
and pooled data. NC¼ not computable. Numbers in brackets denote the prevalence (%) of malignant masses in each centre. Oncology centres
were: University Hospitals Leuven, Belgium (LBE); Universita Cattolica del Sacro Cuore, Rome, Italy (RIT); Ospedale San Gerardo, Monza, Italy
(OIT); General Faculty Hospital, Prague, Czech Republic (PCR); Istituto Europeo di Oncologia, Milan, Italy (CIT); Medical University Lublin, Poland
(LPO); Karolinska University Hospital, Stockholm, Sweden (SSW); Skåne University Hospital Lund, Sweden (LSW); Universita degli Studi di Udine,
Italy (UDI); Istituto Nazionale dei Tumori, Naples, Italy (GIT); University of Bologna, Italy (BIT). Non-oncology centres were: Skåne University
Hospital Malmo¨, Sweden (MSW), Ziekenhuis Oost-Limburg, Genk, Belgium (GBE); Ospedale San Giovanni di Dio, Cagliari, Italy (SIT); DCS Sacco
University of Milan, Italy (MIT); Universita degli Studi di Napoli, Naples, Italy (NIT); Institut Universitari Dexeus, Barcelona, Spain (BSP); Ospedale
dei Bambini Vittore Buzzi, Milan, Italy (FIT).
BRITISH JOURNAL OF CANCER Diagnosing ovarian cancer: evidence from IOTA3
686 www.bjcancer.com |DOI:10.1038/bjc.2014.333
inconclusive or equivocal results of the first stage test could
be referred for SA by an experienced ultrasound examiner.
Each IOTA strategy has its own advantages and disadvantages.
For example, LR1 and LR2 give a continuous result (a risk
estimate) for which the cut off to diagnose malignancy can be
varied depending on the context. The SRs are easier to apply than
LR1 and LR2, which require a computer or mobile application, but
do not offer the flexibility of LR1 and LR2. However, all of these
approaches can be used to either classify all patients or classify a
majority of patients while referring a subset of patients for further
testing. Using SDs as a first stage test offers no substantial
advantages in test performance over the other IOTA strategies that
we evaluated in this work. However, referring patients to expert
examiners with masses in which the SRs do not apply or with
equivocal results of LR2 is advantageous as it leads to a reduction
in the false-positive rate, while only minimally decreasing the
sensitivity. In this study as well as in IOTA phase 2 data, SRs
were inconclusive in 23% of patients, whereas LR2 results were
equivocal in 17–18% of the same patients (Timmerman et al,
2010a; Van Calster et al, 2012). In other validation studies of the
SRs, fewer patients had inconclusive results with reported
percentages between 11 and 21% in different populations
(Fathallah et al, 2011; Hartman et al, 2012; Alca´zar et al, 2013;
Sayasneh et al, 2013b).
The results of IOTA3 show that IOTA methods result in better
discrimination of adnexal pathology before surgical treatment
irrespective of the prevalence of malignant disease. Therefore, the
application of IOTA risk models or rules provide a rational basis
for referral of patients with a mass classified as malignant to
specialist oncology services.
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